ALK-positive non-small cell lung cancer
Clinical research in advanced ALK-positive NSCLC includes treatment-naïve disease and settings with ALK resistance mutations, with attention to patients whose tumors are driven by ALK rearrangements or activating alterations.
- Advanced ALK-positive NSCLC
- Treatment-naïve ALK-driven disease
- ALK resistance mutations
Related work also extends to other solid tumors carrying ALK alterations.
ROS1-positive solid tumors
The sponsor’s research portfolio includes advanced ROS1-positive NSCLC and additional ROS1-positive solid tumors, reflecting a focus on oncogenic ROS1 signaling across lung cancer and broader solid tumor settings.
- Advanced ROS1-positive NSCLC
- ROS1-positive solid tumors
- Oncogenic ROS1 alterations
This area centers on patients with tumors defined by ROS1 rearrangements.
Targeted kinase inhibition
Across its oncology studies, Nuvalent Inc. is focused on selective kinase inhibitors directed at ALK and ROS1, with interest in therapies designed for molecularly defined non-small cell lung cancer and related solid tumors.
- Selective ALK inhibition
- Selective ROS1 inhibition
- Molecularly targeted oncology
The therapeutic emphasis remains on precision oncology for tumors driven by these tyrosine kinase alterations.
